Dr. Claire Madden-Smith is an advisor and investor in the pharmaceutical and healthcare sector. For over 20 years her career focused on the contract services environment, predominantly in pharmaceutical development. In 2018 Juniper Pharmaceuticals was sold to Catalent Inc. for $140m, enabling Claire to fully exit the organisation in 2019.
Claire was an executive director of Molecular Profiles and post-sale in 2013 was Senior Vice-President at Juniper Pharmaceuticals, leading Juniper Pharma Services, a division of the organisation. Claire has a degree and PhD in chemistry from Loughborough University.
Claire was accountable for building and evolving the consistently successful service organisation in both a private and publicly listed setting and from 2014 oversaw the rapid growth of the contract development and manufacturing service line.